Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load < or = 500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.
Antinori
Andrea
A
Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Roma, Italy. antinori@inmi.it
Cozzi-Lepri
Alessandro
A
Ammassari
Adriana
A
Trotta
Maria Paola
MP
Nauwelaers
David
D
Hoetelmans
Richard
R
Murri
Rita
R
Melzi
Sara
S
Narciso
Pasquale
P
Nasta
Paola
P
Zaccarelli
Mauro
M
Santopadre
Paola
P
Vecchiet
Jacopo
J
Izzo
Crescenzo Maria
CM
Maonforte
Antonella d'Arminio
Ad
D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000097:blood*; D006801:Humans; D007558:Italy; D010349:Patient Compliance; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000097:blood*; D011795:Surveys and Questionnaires; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors